Sinotherapeutics (SH:688247) Xin Lang Cai Jing·2025-09-26 08:09Core Viewpoint - The approval of the supplementary application for the new specification of Sitagliptin Metformin Extended-Release Tablets is expected to enhance the company's market competitiveness and share, positively impacting future performance [1] Group 1 - The full subsidiary Jiangsu Xuantai Pharmaceutical Co., Ltd. received the approval notice from the National Medical Products Administration for the supplementary application [1] - The newly approved specification includes "each tablet contains 50mg of Sitagliptin Phosphate (calculated as C₁₆H₁₅F₆N₅O)" and "500mg of Metformin Hydrochloride" [1] - The currently marketed specification is "each tablet contains 50mg of Sitagliptin Phosphate and 1000mg of Metformin Hydrochloride" [1] Group 2 - The new specification is aimed at better meeting patient medication needs [1] - The approval is anticipated to enhance the product's market competitiveness and share [1] - The positive impact on the company's future performance is highlighted [1]